The FDA just made GLP-1 access a national priority. We built the navigation guide.

Last month, the FDA's Commissioner's National Priority Voucher program identified drug affordability as one of five national priorities — creating a fast-track approval pathway for treatments that address cost and access barriers.

For the GLP-1 community, that's significant.

Ozempic, Wegovy, Mounjaro, and Zepbound have changed lives. They've also created a uniquely frustrating experience: a treatment millions of people need, priced out of reach for most, wrapped in insurance bureaucracy, and surrounded by misinformation about compounding, telehealth, and savings programs.

The government is starting to treat that as the emergency it is. We've been treating it that way since day one.

Today we're launching the GLPeople Navigator — a plain-English guide to getting, paying for, and understanding GLP-1 medications.

Three things, one platform:

Lumi — your AI guide to news, FDA updates, and anything worth knowing about the GLP-1 space. Ask her anything at glpeople.ai/ask.

The Navigator — honest, practical, regularly updated guidance on costs, telehealth providers, insurance appeals, savings programs, and what the FDA is doing about access.

The Community — coming soon. A real forum for real conversations with people on the same journey.

No prescriptions. No medical advice. No sponsored opinions dressed up as honest takes.

Just navigation.

→ Start with the Navigator → Meet Lumi → Subscribe to The GLPeople Brief — our weekly newsletter covering everything that matters in the GLP-1 world.